|
第七章 參考文獻
1.Kotzin, B. L. 1996. Systemic lupus erythematosus. Cell 85:303. 2.Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271. 3.McClain, M. T., R. H. Scofield, B. T. Kurien, T. F. Gross, and J. A. James. 2002. Selective small antigenic structures are capable of inducing widespread autoimmunity which closely mimics the humoral fine specificity of human SLE. Scand J Immunol 56:399. 4.Ermann, J., and C. G. Fathman. 2001. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2:759. 5.Levin, M. C., S. M. Lee, F. Kalume, Y. Morcos, F. C. Dohan, Jr., K. A. Hasty, J. C. Callaway, J. Zunt, D. Desiderio, and J. M. Stuart. 2002. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8:509. 6.Dale, J. B., and E. H. Beachey. 1985. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 162:583. 7.James, J. A., K. M. Kaufman, A. D. Farris, E. Taylor-Albert, T. J. Lehman, and J. B. Harley. 1997. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100:3019. 8.Kang, I., T. Quan, H. Nolasco, S. H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft. 2004. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 172:1287. 9.Riemekasten, G., and B. H. Hahn. 2005. Key autoantigens in SLE. Rheumatology (Oxford) 44:975. 10.McClain, M. T., L. D. Heinlen, G. J. Dennis, J. Roebuck, J. B. Harley, and J. A. James. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11:85. 11.James, J. A., T. Gross, R. H. Scofield, and J. B. Harley. 1995. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 181:453. 12.Marrack, P., J. Kappler, and B. L. Kotzin. 2001. Autoimmune disease: why and where it occurs. Nat Med 7:899. 13.Lawman, S., and M. R. Ehrenstein. 2002. Many paths lead to lupus. Lupus 11:801. 14.Napirei, M., H. Karsunky, B. Zevnik, H. Stephan, H. G. Mannherz, and T. Moroy. 2000. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25:177. 15.Wang, H., J. Xu, X. Ji, X. Yang, K. Sun, X. Liu, and Y. Shen. 2005. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus. Cell Immunol 235:117. 16.Barber, D. F., A. Bartolome, C. Hernandez, J. M. Flores, C. Redondo, C. Fernandez-Arias, M. Camps, T. Ruckle, M. K. Schwarz, S. Rodriguez, A. C. Martinez, D. Balomenos, C. Rommel, and A. C. Carrera. 2005. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11:933. 17.Strasser, A., S. Whittingham, D. L. Vaux, M. L. Bath, J. M. Adams, S. Cory, and A. W. Harris. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 88:8661. 18.Balomenos, D., J. Martin-Caballero, M. I. Garcia, I. Prieto, J. M. Flores, M. Serrano, and A. C. Martinez. 2000. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 6:171. 19.Gaynor, B., C. Putterman, P. Valadon, L. Spatz, M. D. Scharff, and B. Diamond. 1997. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A 94:1955. 20.Arbuckle, M. R., M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526. 21.von Muhlen, C. A., and E. M. Tan. 1995. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:323. 22.Moroi, Y., C. Peebles, M. J. Fritzler, J. Steigerwald, and E. M. Tan. 1980. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 77:1627. 23.McClain, M. T., P. A. Ramsland, K. M. Kaufman, and J. A. James. 2002. Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol 168:2054. 24.Sontheimer, R. D., and J. N. Gilliam. 1978. An immunofluorescence assay for double-stranded DNA antibodies using the Crithidia luciliae kinetoplast as a double-stranded DNA substrate. J Lab Clin Med 91:550. 25.Suzuki, N., T. Harada, Y. Mizushima, and T. Sakane. 1993. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J Immunol 151:1128. 26.Zhao, Z., B. Deocharan, P. E. Scherer, L. J. Ozelius, and C. Putterman. 2006. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol 176:7704. 27.Vancikova, Z., and P. Dvorak. 2001. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review. Curr Drug Targets Immune Endocr Metabol Disord 1:179. 28.Fortunato, E. A., A. K. McElroy, I. Sanchez, and D. H. Spector. 2000. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol 8:111. 29.Pomeroy, C., and J. A. Englund. 1987. Cytomegalovirus: epidemiology and infection control. Am J Infect Control 15:107. 30.Clark, B. R., J. A. Zaia, L. Balce-Directo, and Y. P. Ting. 1984. Isolation and partial chemical characterization of a 64,000-dalton glycoprotein of human cytomegalovirus. J Virol 49:279. 31.Ruger, B., S. Klages, B. Walla, J. Albrecht, B. Fleckenstein, P. Tomlinson, and B. Barrell. 1987. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J Virol 61:446. 32.Roby, C., and W. Gibson. 1986. Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J Virol 59:714. 33.Schmolke, S., P. Drescher, G. Jahn, and B. Plachter. 1995. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 69:1071. 34.Liu, B., and M. F. Stinski. 1992. Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J Virol 66:4434. 35.Grefte, A., M. C. Harmsen, M. van der Giessen, S. Knollema, W. J. van Son, and T. H. The. 1994. Presence of human cytomegalovirus (HCMV) immediate early mRNA but not ppUL83 (lower matrix protein pp65) mRNA in polymorphonuclear and mononuclear leukocytes during active HCMV infection. J Gen Virol 75 (Pt 8):1989. 36.Schmolke, S., H. F. Kern, P. Drescher, G. Jahn, and B. Plachter. 1995. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 69:5959. 37.Gilbert, M. J., S. R. Riddell, B. Plachter, and P. D. Greenberg. 1996. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720. 38.Abate, D. A., S. Watanabe, and E. S. Mocarski. 2004. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol 78:10995. 39.Browne, E. P., and T. Shenk. 2003. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci U S A 100:11439. 40.Stoll, M. L., and J. Gavalchin. 2000. Systemic lupus erythematosus-messages from experimental models. Rheumatology (Oxford) 39:18. 41.Satoh, M., and W. H. Reeves. 1994. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 180:2341. 42.Anderson, P. N., and M. Potter. 1969. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 222:994. 43.Satoh, M., A. Kumar, Y. S. Kanwar, and W. H. Reeves. 1995. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 92:10934. 44.Satoh, M., H. B. Richards, V. M. Shaheen, H. Yoshida, M. Shaw, J. O. Naim, P. H. Wooley, and W. H. Reeves. 2000. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 121:399. 45.Chang, M., M. R. Pan, D. Y. Chen, and J. L. Lan. 2006. Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice. Clin Exp Immunol 143:167. 46.Pendergraft, W. F., 3rd, G. A. Preston, R. R. Shah, A. Tropsha, C. W. Carter, Jr., J. C. Jennette, and R. J. Falk. 2004. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72. 47.Beebe, G. W., A. H. Simon, and S. Vivona. 1972. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 95:337.
|